Neuronetics, Inc. (STIM): Price and Financial Metrics


Neuronetics, Inc. (STIM): $11.31

-0.23 (-1.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STIM Stock Summary

  • STIM's went public 2.82 years ago, making it older than merely 7.4% of listed US stocks we're tracking.
  • As for revenue growth, note that STIM's revenue has grown -21.41% over the past 12 months; that beats the revenue growth of merely 18.51% of US companies in our set.
  • In terms of volatility of its share price, STIM is more volatile than 93.4% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Neuronetics Inc, a group of peers worth examining would be AXGN, PWFL, VAPO, LNN, and CHFS.
  • STIM's SEC filings can be seen here. And to visit Neuronetics Inc's official web site, go to www.neurostar.com.

STIM Stock Price Chart Interactive Chart >

Price chart for STIM

STIM Price/Volume Stats

Current price $11.31 52-week high $22.43
Prev. close $11.54 52-week low $1.70
Day low $11.18 Volume 260,000
Day high $11.93 Avg. volume 481,874
50-day MA $14.17 Dividend yield N/A
200-day MA $9.16 Market Cap 291.05M

Neuronetics, Inc. (STIM) Company Bio


Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company’s NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was founded in 2003 and is based in Malvern, Pennsylvania.


STIM Latest News Stream


Event/Time News Detail
Loading, please wait...

STIM Latest Social Stream


Loading social stream, please wait...

View Full STIM Social Stream

Latest STIM News From Around the Web

Below are the latest news stories about Neuronetics Inc that investors may wish to consider to help them evaluate STIM as an investment opportunity.

Neuronetics to Report First Quarter 2021 Financial and Operating Results and Host Conference Call

MALVERN, Pa., April 20, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter financial and operating results prior to market open on Tuesday, May 4, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international call...

Yahoo | April 20, 2021

Neuronetics Announces Appointment of Robert Cascella to its Board of Directors

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Robert A. Cascella to its Board of Directors, effective immediately. Following his appointment, the Neuronetics’ Board of Directors now has eight members. “I am very pleased to have a leader of Rob’s quality and experience join Neuronetics’ Board of Directors,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “His history of value creation in healthcare uniquely qualifies him to help guide Neuronetics as we continue to build upon our market leadership posit...

Yahoo | April 1, 2021

Neuronetics, Inc. (NASDAQ:STIM) Full-Year Results: Here's What Analysts Are Forecasting For This Year

A week ago, Neuronetics, Inc. ( NASDAQ:STIM ) came out with a strong set of annual numbers that could potentially lead...

Yahoo | March 6, 2021

Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations

Company focuses on driving clinical development for NeuroStar® Advanced Therapy System for mental healthMALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced Cory Anderson has been appointed the company’s Vice President, Clinical Affairs and Medical Operations effective as of March 1. “I am excited to welcome Cory to the team and know he’ll make an impact quickly,” said Keith J. Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “We’re laser focused on driving clinical innovation to ensure the millions suffering from depression and other con...

Yahoo | March 3, 2021

Neuronetics, Inc. (STIM) Q4 2020 Earnings Call Transcript

Good morning, and thank you for joining us for Neuronetics' fourth-quarter 2020 conference call. Joining me on today's call are Neuronetics president and chief executive officer, Keith Sullivan; and chief financial officer, Steve Furlong.

Yahoo | March 3, 2021

Read More 'STIM' Stories Here

STIM Price Returns

1-mo -10.17%
3-mo -46.83%
6-mo 101.60%
1-year 423.61%
3-year N/A
5-year N/A
YTD 1.80%
2020 147.44%
2019 -76.80%
2018 N/A
2017 N/A
2016 N/A

Continue Researching STIM

Here are a few links from around the web to help you further your research on Neuronetics Inc's stock as an investment opportunity:

Neuronetics Inc (STIM) Stock Price | Nasdaq
Neuronetics Inc (STIM) Stock Quote, History and News - Yahoo Finance
Neuronetics Inc (STIM) Stock Price and Basic Information | MarketWatch

Page generated in 1.1277 seconds.